Press Releases Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022 November 10, 2022 Read More » InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week October 26, 2022 Read More » InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update September 23, 2022 Read More » InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market September 13, 2022 Read More » InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market September 9, 2022 Read More » InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business September 8, 2022 Read More » InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria August 23, 2022 Read More » InMed Announces Changes to its Board of Directors August 9, 2022 Read More » InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa July 25, 2022 Read More » InMed Announces Appointment of Chief Operating Officer July 18, 2022 Read More » InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance July 12, 2022 Read More » InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions June 14, 2022 Read More » InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector June 9, 2022 Read More » InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules June 6, 2022 Read More » InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules June 2, 2022 Read More » InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update May 13, 2022 Read More » InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV May 2, 2022 Read More » InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert April 28, 2022 Read More » InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert April 28, 2022 Read More » InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector April 21, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022 November 10, 2022 Read More »
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update September 23, 2022 Read More »
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market September 13, 2022 Read More »
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market September 9, 2022 Read More »
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business September 8, 2022 Read More »
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa July 25, 2022 Read More »
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance July 12, 2022 Read More »
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions June 14, 2022 Read More »
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector June 9, 2022 Read More »
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules June 6, 2022 Read More »
InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules June 2, 2022 Read More »
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update May 13, 2022 Read More »
InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV May 2, 2022 Read More »
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert April 28, 2022 Read More »
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert April 28, 2022 Read More »
InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector April 21, 2022 Read More »
